Latest Biotech News

UCB disclosed plans to acquire clinical-stage epilepsy developer Neurona Therapeutics for $650 million, with potential milestone payments up to $500 million. The move is intended to broaden UCB’s...

Revolution Medicine reported striking Phase III outcomes for its once-daily oral KRAS-pathway candidate daraxonrasib (RASolute 302) in metastatic pancreatic ductal adenocarcinoma after prior...

Noscendo is pursuing clinical actionability and cost evidence for its cfDNA metagenomic sequencing platform in sepsis through a new €7.5 million German project. The effort, called OptiSep, will...

10x Genomics unveiled its Atera spatial instrument at AACR 2026, positioning the platform as whole-transcriptome spatial biology at scale. The company says Atera addresses trade-offs seen with...

Breakthrough Prize Foundation awarded the Life Sciences prize to teams credited with pioneering gene therapies for two genetic disease areas. The coverage highlights Jean Bennett, Albert Maguire,...

Breakthrough Prize recognition also extended to work identifying a shared genetic cause of ALS and FTD. The coverage credits Rosa Rademakers and Bryan Traynor with identifying the most common...

Researchers reported that wastewater surveillance can detect the emergence of drug-resistant Candida auris strains in healthcare settings, using wastewater-based epidemiology. The findings were...

Odyssey Therapeutics is attempting an IPO again after pulling its first attempt earlier, according to coverage that says the company submitted a second registration. The update signals continued...

KRAS drug developers are advancing to the next generation of targeted therapies for lung cancer, according to early-cut data highlighted in a new report from San Diego. The coverage points to...

UCB announced plans to buy Neurona Therapeutics in a deal valued at $650 million, with up to $500 million in milestone payments, to broaden its clinical-stage epilepsy portfolio. The transaction...

Revolution Medicines reported standout Phase III data for its once-daily oral daraxonrasib in metastatic pancreatic ductal adenocarcinoma, with investors reacting strongly to the early readout. In...

Obsidian Therapeutics moved to combine with Galera Therapeutics in a merger that brings $350 million in funding earmarked for cancer drug trials. The transaction is positioned around Obsidian’s...

Odyssey Therapeutics is preparing a second attempt at an initial public offering after withdrawing its first try a year earlier. The Boston-based company filed for the IPO again, aiming to take...

10x Genomics unveiled its Atera spatial platform at AACR 2026, positioning the instrument for whole-transcriptome spatial biology at scale. Company leadership said Atera addresses measurement...

New reporting describes how automation and AI are changing organoid research workflows, enabling teams to move beyond traditional 2D cell culture and animal models. The article frames organoids as...

The Breakthrough Prize Foundation honored gene therapy pioneers with the 2026 Breakthrough Prize for Life Sciences, spotlighting teams behind landmark advances that helped establish clinical gene...

A preclinical study reported a bacterial-vaccine approach to boosting colorectal cancer therapy in mice by combining immune checkpoint inhibitors with an oral bread-based formulation. The report...

Researchers reported that wastewater-based epidemiology can detect the emergence of clinically significant, drug-resistant Candida auris strains within healthcare settings. The work, described as...

Revolution Medicines said its once-daily oral daraxonrasib produced a statistically and clinically meaningful overall survival benefit in its Phase III RASolute 302 trial in metastatic pancreatic...

Obsidian Therapeutics announced a merger with Galera Therapeutics that includes a $350 million infusion aimed at advancing its tumor-infiltrating lymphocyte (TIL) pipeline. The deal would bring...